EYPT
EYPT
NASDAQ · Pharmaceuticals

Eyepoint Inc

$13.89
+1.06 (+8.26%)
As of Aug 8, 10:11 PM ET ·
Financial Highlights (FY 2026)
Revenue
37.84M
Net Income
-279,803,213
Gross Margin
93.4%
Profit Margin
-739.4%
Rev Growth
-8.8%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 93.4% 93.4% 35.0% 35.0%
Operating Margin -776.0% -698.4% 22.3% 21.7%
Profit Margin -739.4% -702.5% 24.9% 20.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 37.84M 41.51M 211.34M 213.20M
Gross Profit 35.35M 38.77M 73.87M 74.52M
Operating Income -293,659,713 -289,891,128 47.20M 46.31M
Net Income -279,803,213 -276,212,451 52.60M 44.43M
Gross Margin 93.4% 93.4% 35.0% 35.0%
Operating Margin -776.0% -698.4% 22.3% 21.7%
Profit Margin -739.4% -702.5% 24.9% 20.8%
Rev Growth -8.8% -8.8% -6.2% +21.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 107.95M 96.71M
Total Equity 420.20M 423.48M
D/E Ratio 0.26 0.23
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -290,856,796 -303,075,525 60.54M 58.90M
Free Cash Flow 38.74M 42.58M